Design, Synthesis, Computer Modeling and Analgesic Activity of Some New Disubstituted Quinazolin-4(3H)-ones

Ayyad, Rezk A; Sakr, Helmy

doi:10.4172/2161-0444.1000360

Cited by 4 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On standing for 1 h, solidification occur, the product was filtered off, washed with water and dried. (6)(7)(8)(9)(10)(11)(12)(13)(14): To a solution of the appropriate acetophenones (0.01mol) dissolved in ethanol (20ml), was added different substituted 3-amino-2-phenylquinazolin-4-one derivative (5a-5c) (0.01mol) and pH of the resultant solution was adjusted to 4.0-4.5 using glacial acetic acid. The resulting mixture was refluxed for 2-3 h. The solid thus obtained was filtered and purified by column chromatographic method using n-hexane/ethyl acetate (75:25) as eluents.…”

Section: Methodsmentioning

confidence: 99%

“…The in silico pharmacokinetic properties of the designed quinazoline analogues (6)(7)(8)(9)(10)(11)(12)(13)(14) were estimated by means of molecular weight, dipole moment, H-bond donors, H-bond acceptors, QPlogP o/w, QPlogS, QlogBB, human oral absorption, and polar surface area (PSA), molecular surface descriptors (solvent accessible surface area) and other parameters such as wiener index (WI) were also determined using QikProp (version9.2) module of Schrödinger. As well as the Lipinski' rule of five was to filter molecules with filter for drug-like properties has also been estimated.…”

Section: Prediction Of Pharmacokinetic Parameter (In Silico)mentioning

confidence: 99%

“…Unless otherwise stated, the following conditions were employed in all experiments. Target compounds (6)(7)(8)(9)(10)(11)(12)(13)(14) were suspended in aqueous solution of carboxymethyl cellulose (CMC, 0.5% w/v) and administered orally at a dose level of 10mg/kg of synthesized compounds (6)(7)(8)(9)(10)(11)(12)(13)(14), respectively. Control animals were similarly treated with aqueous solution of carboxymethyl cellulose (CMC, 0.5% w/v).…”

Section: -[2-(4-chlorophenyl)-ethylimino]-2-(2-chlorophenyl)-quinazomentioning

confidence: 99%

“…Structures of the ligands 2,3-disubstituted quinazolinone derivatives containing Schiff bases (6)(7)(8)(9)(10)(11)(12)(13)(14) were drawn by using chemdraw ultra 8.0 and the three-dimensional structures of the compounds were constructed using the Maestro interface. All 3D ligands were subjected to energy minimization and optimization using Ligprep module.…”

Section: Preparation Of Ligandsmentioning

confidence: 99%

“…Quinazolin-4(3H)-one represents a versatile lead molecule for the design of potential bioactive agents [1][2][3][4][5][6][7] and the pharmaceuticals containing quinazolinone nucleus show varied biological activities as different substitution patterns results in diverse biological properties [8][9][10] . Number of quinazoline derivatives with different substitutions at 2,3,4,6 positions have been reported and studied as antitumor 11 , antibacterial 12 , anticonvulsant 13 , antimalarials 14 and antiviral agents 15 as shown in Table 1.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Untitled

2017

IJPSR

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Prediction Of Pharmacokinetic Parameter (In Silico)mentioning

confidence: 99%

Section: -[2-(4-chlorophenyl)-ethylimino]-2-(2-chlorophenyl)-quinazomentioning

confidence: 99%

Section: Preparation Of Ligandsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Untitled

2017

IJPSR

View full text Add to dashboard Cite

Beta-1 Receptor (β1) in the Heart Specific Indicate to Stereoselectivity

Rezk Rezk,

Ahmed Mohamed,

Ahmed Mohamed

et al. 2024

Arch Pharm Pharma Sci

View full text Add to dashboard Cite

The β1 receptor is one of the three beta receptors present in the human body, namely β1, β2, and β3. The β1 receptor is predominantly located in the heart, where it plays a crucial role in regulating the heart rate and the force of contraction, thereby increasing the cardiac output and the efficiency of blood pumping throughout the body. This receptor is targeted by a variety of pharmaceutical agents known as beta-blockers, which are commonly used in the treatment of cardiovascular conditions such as hypertension, angina, and arrhythmias.The β1 receptor exhibits stereoselectivity, meaning that different enantiomers (chiral molecules) of beta blockers can have varying levels of effectiveness and side effects. This study focuses on the stereoselectivity of the β1 receptor and the clinical implications of this property. It includes an examination of various β1 blockers, such as propranolol (a non-selective beta blocker), and selective β1 blockers like atenolol, bisoprolol, nebivolol, metoprolol, esmolol, acebutolol, and betaxolol. Each of these drugs has a unique chemical structure, with specific functional groups that contribute to their selective action on the β1 receptor. Furthermore, the β2 receptor, which is mainly present in the bronchi and bronchioles, is responsible for bronchodilation, and the β3 receptor, found in the bladder, helps reduce urinary urgency. Understanding the distinct locations and functions of these receptors allows for the development of targeted therapies with minimal off-target effects. This review highlights the importance of stereoselectivity in the development and use of β1 blockers, discussing their chemical structures, pharmacological activities, and therapeutic uses. It also explores the potential for future research and development of more selective and effective β1 receptor agonists and antagonists, which could offer improved therapeutic outcomes for patients with cardiovascular diseases. This study underscores the significant role of the β1 receptor in cardiovascular health and provides insights into the ongoing advancements in beta-blocker therapy. By delving into the stereoselectivity and specific actions of these drugs, the research aims to enhance the understanding and optimization of β1 receptor-targeted treatments in clinical practice.

show abstract

New Quinazolin-4(3H)-one Derivatives Incorporating Hydrazone and Pyrazole Scaffolds as Antimicrobial Agents Targeting DNA Gyraze Enzyme

2022

View full text Add to dashboard Cite

The present work includes the synthesis of a new series of quinazolin-4(3H)-one compounds (4a–f, 5a–d) as antimicrobial agents. The starting compound, 2-hydrazinylquinazolin-4(3H)-one (2), was synthesized and treated with different carbonyl compounds to afford the hydrazone derivatives 4a–f. In addition, the hydrazone derivatives 4a–d were treated with a DMF/POCl3 mixture to give the formyl-pyrazole derivatives 5a–d. All the target compounds were evaluated as antimicrobial agents against four bacterial and four fungal strains. The majority of the tested compounds showed potent antimicrobial activity compared with the reference antibiotics. The most potent antimicrobial activity was shown by 5a with MIC values in the range (1–16) μg/mL. In addition, the most potent compounds against E. coli were evaluated for their inhibitory activity against E. coli DNA gyrase, whereas the target compounds 4a, 5a, 5c, and 5d showed the most potent inhibition to the target enzyme with IC50 values ranging from 3.19 to 4.17 µM. Furthermore, molecular docking studies were performed for the most active compounds against the target E. coli DNA gyrase to determine their binding affinity within the enzyme’s active site. Moreover, ADME evaluations of these compounds predicted their high oral bioavailability and good GI absorption.

show abstract

Design, Synthesis, Computer Modeling and Analgesic Activity of Some New Disubstituted Quinazolin-4(3H)-ones

Cited by 4 publications

References 17 publications

Untitled

Untitled

Beta-1 Receptor (β1) in the Heart Specific Indicate to Stereoselectivity

New Quinazolin-4(3H)-one Derivatives Incorporating Hydrazone and Pyrazole Scaffolds as Antimicrobial Agents Targeting DNA Gyraze Enzyme

Contact Info

Product

Resources

About